Neotherix has been successful in its application for a Collaborative R&D grant from the Technology Strategy Board (TSB). The award is for the development of the "RegeniTherix" wound treatment and monitoring system. Neotherix will be the lead partner in a consortium with Complement Genomics Ltd, SensaPharm Ltd (previously Cord8 Ltd) and the National Physical Laboratory. Durham and Nottingham Universities are also involved as consultants and clinical work will be conducted at James Cook University Hospital in Middlesbrough. The overall project value is £1.14m with a likely project start date in September. The proposed RegeniTherix system is a novel wound device incorporating both a biodegradable tissue scaffold and a removable hydrogel layer to enable detailed and rapid evaluation of the wound. The intimate association of migrating cells from the wound with both scaffold and gel will allow a rapid 'biological' profile of the wound to be determined from the cells involved in the repair process, rather than from exudate or other components subject to degradation. We will achieve this by rapid proteomic analysis of both diffusible factors and cells sampled from the gel via a point of care testing device incorporating a protein chip detecting novel, indicative protein signatures. Use of the system for sampling and analysis of markers of wound status will address a specific unmet clinical need, enabling more focused treatment decisions in the management of problem wounds. Links to Complement Genomics Ltd  , SensaPharm Ltd and National Physical Laboratory |
